The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis

Carla M. Odio, Idis Faingezicht, Maria Paris, Martin Nassar, Aristides Baltodano, Jodi Rogers, Xavier Sáez-Llorens, Kurt D. Olsen, George H. Mccracken

Research output: Contribution to journalArticle

370 Citations (Scopus)

Abstract

Background. In experimental models of meningitis and in children with meningitis, dexamethasone has been shown to reduce meningeal inflammation and to improve the outcome of disease. Methods. We conducted a placebo-controlled, double-blind trial of dexamethasone therapy in 101 infants and children admitted to the National Children's Hospital, San José, Costa Rica, who had culture-proved bacterial meningitis or clinical signs of meningitis and findings characteristic of bacterial infection on examination of the cerebrospinal fluid. The patients were randomly assigned to receive either dexamethasone and cefotaxime (n = 52) or cefotaxime plus placebo (n = 49). Dexamethasone (0.15 mg per kilogram of body weight) was given 15 to 20 minutes before the first dose of cefotaxime and was continued every 6 hours thereafter for four days. Results. The demographic, clinical, and laboratory profiles were similar for the patients in the two treatment groups. By 12 hours after the beginning of therapy, the mean opening cerebrospinal pressure and the estimated cerebral perfusion pressure had improved significantly in the dexamethasone-treated children but worsened in the children treated only with cefotaxime (controls). At 12 hours meningeal inflammation and the concentrations of two cytokines (tumor necrosis factor α and platelet-activating factor) in the cerebrospinal fluid had decreased in the dexamethasone-treated children, whereas in the controls the inflammatory response in the cerebrospinal fluid had increased. At 24 hours the clinical condition and mean prognostic score were significantly better among those treated with dexamethasone than among the controls. At follow-up examination after a mean of 15 months, 7 of the surviving 51 dexamethasone-treated children (14 percent) and 18 of 48 surviving controls (38 percent) had one or more neurologic or audiologic sequelae (P = 0.007); the relative risk of sequelae for a child receiving placebo as compared with a child receiving dexamethasone was 3.8 (95 percent confidence interval, 1.3 to 11.5). Conclusions. The results of this study, in which dexamethasone administration began before the initiation of cefotaxime therapy, provide additional evidence of a beneficial effect of dexamethasone therapy in infants and children with bacterial meningitis.

Original languageEnglish (US)
Pages (from-to)1525-1531
Number of pages7
JournalNew England Journal of Medicine
Volume324
Issue number22
StatePublished - May 30 1991

Fingerprint

Bacterial Meningitides
Dexamethasone
Cefotaxime
Meningitis
Cerebrospinal Fluid
Placebos
Cerebrovascular Circulation
Inflammation
Therapeutics
Costa Rica
Platelet Activating Factor
Bacterial Infections
Nervous System
Theoretical Models
Tumor Necrosis Factor-alpha
Body Weight
Demography
Confidence Intervals
Cytokines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Odio, C. M., Faingezicht, I., Paris, M., Nassar, M., Baltodano, A., Rogers, J., ... Mccracken, G. H. (1991). The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. New England Journal of Medicine, 324(22), 1525-1531.

The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. / Odio, Carla M.; Faingezicht, Idis; Paris, Maria; Nassar, Martin; Baltodano, Aristides; Rogers, Jodi; Sáez-Llorens, Xavier; Olsen, Kurt D.; Mccracken, George H.

In: New England Journal of Medicine, Vol. 324, No. 22, 30.05.1991, p. 1525-1531.

Research output: Contribution to journalArticle

Odio, CM, Faingezicht, I, Paris, M, Nassar, M, Baltodano, A, Rogers, J, Sáez-Llorens, X, Olsen, KD & Mccracken, GH 1991, 'The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis', New England Journal of Medicine, vol. 324, no. 22, pp. 1525-1531.
Odio CM, Faingezicht I, Paris M, Nassar M, Baltodano A, Rogers J et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. New England Journal of Medicine. 1991 May 30;324(22):1525-1531.
Odio, Carla M. ; Faingezicht, Idis ; Paris, Maria ; Nassar, Martin ; Baltodano, Aristides ; Rogers, Jodi ; Sáez-Llorens, Xavier ; Olsen, Kurt D. ; Mccracken, George H. / The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. In: New England Journal of Medicine. 1991 ; Vol. 324, No. 22. pp. 1525-1531.
@article{eb52aec023a7436ca7ffc98ba29fa81d,
title = "The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis",
abstract = "Background. In experimental models of meningitis and in children with meningitis, dexamethasone has been shown to reduce meningeal inflammation and to improve the outcome of disease. Methods. We conducted a placebo-controlled, double-blind trial of dexamethasone therapy in 101 infants and children admitted to the National Children's Hospital, San Jos{\'e}, Costa Rica, who had culture-proved bacterial meningitis or clinical signs of meningitis and findings characteristic of bacterial infection on examination of the cerebrospinal fluid. The patients were randomly assigned to receive either dexamethasone and cefotaxime (n = 52) or cefotaxime plus placebo (n = 49). Dexamethasone (0.15 mg per kilogram of body weight) was given 15 to 20 minutes before the first dose of cefotaxime and was continued every 6 hours thereafter for four days. Results. The demographic, clinical, and laboratory profiles were similar for the patients in the two treatment groups. By 12 hours after the beginning of therapy, the mean opening cerebrospinal pressure and the estimated cerebral perfusion pressure had improved significantly in the dexamethasone-treated children but worsened in the children treated only with cefotaxime (controls). At 12 hours meningeal inflammation and the concentrations of two cytokines (tumor necrosis factor α and platelet-activating factor) in the cerebrospinal fluid had decreased in the dexamethasone-treated children, whereas in the controls the inflammatory response in the cerebrospinal fluid had increased. At 24 hours the clinical condition and mean prognostic score were significantly better among those treated with dexamethasone than among the controls. At follow-up examination after a mean of 15 months, 7 of the surviving 51 dexamethasone-treated children (14 percent) and 18 of 48 surviving controls (38 percent) had one or more neurologic or audiologic sequelae (P = 0.007); the relative risk of sequelae for a child receiving placebo as compared with a child receiving dexamethasone was 3.8 (95 percent confidence interval, 1.3 to 11.5). Conclusions. The results of this study, in which dexamethasone administration began before the initiation of cefotaxime therapy, provide additional evidence of a beneficial effect of dexamethasone therapy in infants and children with bacterial meningitis.",
author = "Odio, {Carla M.} and Idis Faingezicht and Maria Paris and Martin Nassar and Aristides Baltodano and Jodi Rogers and Xavier S{\'a}ez-Llorens and Olsen, {Kurt D.} and Mccracken, {George H.}",
year = "1991",
month = "5",
day = "30",
language = "English (US)",
volume = "324",
pages = "1525--1531",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis

AU - Odio, Carla M.

AU - Faingezicht, Idis

AU - Paris, Maria

AU - Nassar, Martin

AU - Baltodano, Aristides

AU - Rogers, Jodi

AU - Sáez-Llorens, Xavier

AU - Olsen, Kurt D.

AU - Mccracken, George H.

PY - 1991/5/30

Y1 - 1991/5/30

N2 - Background. In experimental models of meningitis and in children with meningitis, dexamethasone has been shown to reduce meningeal inflammation and to improve the outcome of disease. Methods. We conducted a placebo-controlled, double-blind trial of dexamethasone therapy in 101 infants and children admitted to the National Children's Hospital, San José, Costa Rica, who had culture-proved bacterial meningitis or clinical signs of meningitis and findings characteristic of bacterial infection on examination of the cerebrospinal fluid. The patients were randomly assigned to receive either dexamethasone and cefotaxime (n = 52) or cefotaxime plus placebo (n = 49). Dexamethasone (0.15 mg per kilogram of body weight) was given 15 to 20 minutes before the first dose of cefotaxime and was continued every 6 hours thereafter for four days. Results. The demographic, clinical, and laboratory profiles were similar for the patients in the two treatment groups. By 12 hours after the beginning of therapy, the mean opening cerebrospinal pressure and the estimated cerebral perfusion pressure had improved significantly in the dexamethasone-treated children but worsened in the children treated only with cefotaxime (controls). At 12 hours meningeal inflammation and the concentrations of two cytokines (tumor necrosis factor α and platelet-activating factor) in the cerebrospinal fluid had decreased in the dexamethasone-treated children, whereas in the controls the inflammatory response in the cerebrospinal fluid had increased. At 24 hours the clinical condition and mean prognostic score were significantly better among those treated with dexamethasone than among the controls. At follow-up examination after a mean of 15 months, 7 of the surviving 51 dexamethasone-treated children (14 percent) and 18 of 48 surviving controls (38 percent) had one or more neurologic or audiologic sequelae (P = 0.007); the relative risk of sequelae for a child receiving placebo as compared with a child receiving dexamethasone was 3.8 (95 percent confidence interval, 1.3 to 11.5). Conclusions. The results of this study, in which dexamethasone administration began before the initiation of cefotaxime therapy, provide additional evidence of a beneficial effect of dexamethasone therapy in infants and children with bacterial meningitis.

AB - Background. In experimental models of meningitis and in children with meningitis, dexamethasone has been shown to reduce meningeal inflammation and to improve the outcome of disease. Methods. We conducted a placebo-controlled, double-blind trial of dexamethasone therapy in 101 infants and children admitted to the National Children's Hospital, San José, Costa Rica, who had culture-proved bacterial meningitis or clinical signs of meningitis and findings characteristic of bacterial infection on examination of the cerebrospinal fluid. The patients were randomly assigned to receive either dexamethasone and cefotaxime (n = 52) or cefotaxime plus placebo (n = 49). Dexamethasone (0.15 mg per kilogram of body weight) was given 15 to 20 minutes before the first dose of cefotaxime and was continued every 6 hours thereafter for four days. Results. The demographic, clinical, and laboratory profiles were similar for the patients in the two treatment groups. By 12 hours after the beginning of therapy, the mean opening cerebrospinal pressure and the estimated cerebral perfusion pressure had improved significantly in the dexamethasone-treated children but worsened in the children treated only with cefotaxime (controls). At 12 hours meningeal inflammation and the concentrations of two cytokines (tumor necrosis factor α and platelet-activating factor) in the cerebrospinal fluid had decreased in the dexamethasone-treated children, whereas in the controls the inflammatory response in the cerebrospinal fluid had increased. At 24 hours the clinical condition and mean prognostic score were significantly better among those treated with dexamethasone than among the controls. At follow-up examination after a mean of 15 months, 7 of the surviving 51 dexamethasone-treated children (14 percent) and 18 of 48 surviving controls (38 percent) had one or more neurologic or audiologic sequelae (P = 0.007); the relative risk of sequelae for a child receiving placebo as compared with a child receiving dexamethasone was 3.8 (95 percent confidence interval, 1.3 to 11.5). Conclusions. The results of this study, in which dexamethasone administration began before the initiation of cefotaxime therapy, provide additional evidence of a beneficial effect of dexamethasone therapy in infants and children with bacterial meningitis.

UR - http://www.scopus.com/inward/record.url?scp=0025876403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025876403&partnerID=8YFLogxK

M3 - Article

VL - 324

SP - 1525

EP - 1531

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -